{"id":62635,"date":"2026-04-08T20:58:27","date_gmt":"2026-04-08T12:58:27","guid":{"rendered":"https:\/\/flcube.com\/?p=62635"},"modified":"2026-04-08T20:58:29","modified_gmt":"2026-04-08T12:58:29","slug":"gilead-sciences-to-acquire-tubulis-for-3-15b-upfront-adding-next-generation-adcs-tub-040-and-tub-030-to-oncology-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62635","title":{"rendered":"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline"},"content":{"rendered":"\n<p><strong>Gilead Sciences Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>)<\/strong> announced a definitive agreement to acquire <strong>Tubulis GmbH<\/strong>, a German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), for <strong>$3.15 billion upfront<\/strong> plus <strong>up to $1.85 billion in contingent milestone payments<\/strong>. The acquisition significantly strengthens Gilead&#8217;s oncology pipeline with two clinical-stage ADC assets targeting platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), and multiple solid tumor types.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Gilead Sciences Inc. (NASDAQ: GILD)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Tubulis GmbH (Germany)<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>$3.15 billion upfront + up to $1.85 billion milestones<\/td><\/tr><tr><td><strong>Basis<\/strong><\/td><td>Cash-free, debt-free (subject to customary adjustments)<\/td><\/tr><tr><td><strong>Payment Structure<\/strong><\/td><td>Upfront cash payment with contingent milestone payments<\/td><\/tr><tr><td><strong>Expected Close<\/strong><\/td><td>Q2 2026<\/td><\/tr><tr><td><strong>Conditions<\/strong><\/td><td>Regulatory waiting period expiration and customary closing conditions<\/td><\/tr><tr><td><strong>Strategic Focus<\/strong><\/td><td>High unmet medical need oncology indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-asset-portfolio\">Core Asset Portfolio<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tub-040-napi2b-targeting-adc\">TUB-040: NaPi2b-Targeting ADC<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: NaPi2b (sodium-dependent phosphate transport protein 2B)<\/li>\n\n\n\n<li><strong>Payload<\/strong>: Topoisomerase I inhibitor (TOPO1i)<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Phase Ib\/II clinical trials<\/li>\n\n\n\n<li><strong>Indications<\/strong>: Platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC)<\/li>\n\n\n\n<li><strong>Therapeutic Rationale<\/strong>: Addresses significant unmet need in treatment-resistant cancers<\/li>\n\n\n\n<li><strong>Competitive Position<\/strong>: NaPi2b represents emerging target with limited competitive landscape<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-tub-030-5t4-targeting-adc\">TUB-030: 5T4-Targeting ADC<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: 5T4 (trophoblast glycoprotein, oncofetal antigen)<\/li>\n\n\n\n<li><strong>Development Stage<\/strong>: Early clinical development with encouraging data<\/li>\n\n\n\n<li><strong>Indication Scope<\/strong>: Multiple solid tumor types<\/li>\n\n\n\n<li><strong>Clinical Profile<\/strong>: Demonstrated promising preliminary efficacy and safety signals<\/li>\n\n\n\n<li><strong>Target Validation<\/strong>: 5T4 widely expressed across epithelial cancers with limited normal tissue expression<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-pipeline-enhancement\">Strategic Rationale &amp; Pipeline Enhancement<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-gilead-s-oncology-transformation\">Gilead&#8217;s Oncology Transformation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Leadership<\/strong>: Builds on Gilead&#8217;s established ADC expertise through Trodelvy (sacituzumab govitecan)<\/li>\n\n\n\n<li><strong>Pipeline Diversification<\/strong>: Expands beyond current focus areas into new target classes and indications<\/li>\n\n\n\n<li><strong>Technology Integration<\/strong>: Leverages Tubulis&#8217; next-generation ADC platform capabilities<\/li>\n\n\n\n<li><strong>Commercial Synergy<\/strong>: Potential integration with existing oncology commercial infrastructure<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-high-unmet-medical-need-focus\">High Unmet Medical Need Focus<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platinum-Resistant Ovarian Cancer<\/strong>: Limited effective treatment options with poor prognosis<\/li>\n\n\n\n<li><strong>NSCLC Subpopulations<\/strong>: Addresses specific molecular subsets with inadequate current therapies<\/li>\n\n\n\n<li><strong>Solid Tumor Expansion<\/strong>: Broad applicability across multiple hard-to-treat cancers<\/li>\n\n\n\n<li><strong>Target Selection<\/strong>: Both NaPi2b and 5T4 represent validated but underexploited targets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-structure-amp-valuation-analysis\">Financial Structure &amp; Valuation Analysis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-economics\">Deal Economics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Potential Value<\/strong>: Up to $5.0 billion ($3.15B upfront + $1.85B milestones)<\/li>\n\n\n\n<li><strong>Upfront Premium<\/strong>: Represents significant premium for clinical-stage biotech assets<\/li>\n\n\n\n<li><strong>Milestone Structure<\/strong>: Performance-based payments align with development and commercial success<\/li>\n\n\n\n<li><strong>Cash Impact<\/strong>: Manageable given Gilead&#8217;s strong balance sheet and cash position<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-investment-rationale\">Investment Rationale<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Risk-Adjusted Returns<\/strong>: Milestone structure provides downside protection while capturing upside potential<\/li>\n\n\n\n<li><strong>Platform Value<\/strong>: Acquisition includes not just assets but proprietary ADC technology platform<\/li>\n\n\n\n<li><strong>Time-to-Market Advantage<\/strong>: Clinical-stage assets provide faster path to commercialization versus internal discovery<\/li>\n\n\n\n<li><strong>Competitive Positioning<\/strong>: Secures assets ahead of potential bidding competition<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-adc-market-dynamics\">ADC Market Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rapid Growth<\/strong>: Antibody-drug conjugate market experiencing explosive growth with multiple recent approvals<\/li>\n\n\n\n<li><strong>Technology Evolution<\/strong>: Next-generation ADCs focusing on improved therapeutic index and novel targets<\/li>\n\n\n\n<li><strong>M&amp;A Activity<\/strong>: Increasing consolidation as large pharma seeks to access innovative ADC platforms<\/li>\n\n\n\n<li><strong>Valuation Trends<\/strong>: Premium valuations for clinical-stage ADC assets with novel targets<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-positioning\">Competitive Positioning<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NaPi2b Landscape<\/strong>: Limited competition with few companies advancing NaPi2b-targeting therapies<\/li>\n\n\n\n<li><strong>5T4 Development<\/strong>: Historical challenges with 5T4-targeting approaches, but newer ADC formats showing promise<\/li>\n\n\n\n<li><strong>Payload Differentiation<\/strong>: TOPO1i payload represents proven but optimized approach<\/li>\n\n\n\n<li><strong>Gilead&#8217;s ADC Portfolio<\/strong>: Complements Trodelvy with different targets and mechanisms<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-integration-strategy-amp-development-pathway\">Integration Strategy &amp; Development Pathway<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-development-acceleration\">Clinical Development Acceleration<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase Ib\/II Continuation<\/strong>: Maintain ongoing trials while leveraging Gilead&#8217;s clinical development expertise<\/li>\n\n\n\n<li><strong>Regulatory Strategy<\/strong>: Utilize Gilead&#8217;s global regulatory capabilities for accelerated pathways<\/li>\n\n\n\n<li><strong>Trial Design Optimization<\/strong>: Apply lessons learned from Trodelvy development to enhance trial efficiency<\/li>\n\n\n\n<li><strong>Combination Strategies<\/strong>: Explore rational combinations with Gilead&#8217;s existing oncology portfolio<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-preparation\">Commercial Preparation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access Planning<\/strong>: Early engagement with payers and healthcare systems<\/li>\n\n\n\n<li><strong>Physician Education<\/strong>: Leverage existing oncology relationships for rapid adoption<\/li>\n\n\n\n<li><strong>Manufacturing Scale-up<\/strong>: Utilize Gilead&#8217;s established ADC manufacturing capabilities<\/li>\n\n\n\n<li><strong>Global Rollout<\/strong>: Coordinated international launch strategy leveraging Gilead&#8217;s global infrastructure<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Commitment<\/strong>: Reinforces Gilead&#8217;s long-term commitment to becoming a leading oncology company<\/li>\n\n\n\n<li><strong>European Innovation Access<\/strong>: Provides access to cutting-edge European biotech innovation<\/li>\n\n\n\n<li><strong>ADC Platform Enhancement<\/strong>: Strengthens Gilead&#8217;s internal ADC capabilities through technology transfer<\/li>\n\n\n\n<li><strong>Shareholder Value<\/strong>: Potential for significant long-term value creation through successful asset development<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding acquisition completion, clinical development, and financial performance. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, and integration challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a German&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,226,1025],"class_list":["post-62635","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-gilead-sciences","tag-nasdaq-gild"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront plus up to $1.85 billion in contingent milestone payments. The acquisition significantly strengthens Gilead&#039;s oncology pipeline with two clinical-stage ADC assets targeting platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), and multiple solid tumor types.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62635\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront plus up to $1.85 billion in contingent milestone payments. The acquisition significantly strengthens Gilead&#039;s oncology pipeline with two clinical-stage ADC assets targeting platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), and multiple solid tumor types.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62635\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T12:58:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T12:58:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62635#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62635\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline\",\"datePublished\":\"2026-04-08T12:58:27+00:00\",\"dateModified\":\"2026-04-08T12:58:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62635\"},\"wordCount\":721,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Gilead Sciences\",\"NASDAQ: GILD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62635#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62635\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62635\",\"name\":\"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-08T12:58:27+00:00\",\"dateModified\":\"2026-04-08T12:58:29+00:00\",\"description\":\"Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront plus up to $1.85 billion in contingent milestone payments. The acquisition significantly strengthens Gilead's oncology pipeline with two clinical-stage ADC assets targeting platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), and multiple solid tumor types.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62635#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62635\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62635#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront plus up to $1.85 billion in contingent milestone payments. The acquisition significantly strengthens Gilead's oncology pipeline with two clinical-stage ADC assets targeting platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), and multiple solid tumor types.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62635","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline","og_description":"Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront plus up to $1.85 billion in contingent milestone payments. The acquisition significantly strengthens Gilead's oncology pipeline with two clinical-stage ADC assets targeting platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), and multiple solid tumor types.","og_url":"https:\/\/flcube.com\/?p=62635","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-08T12:58:27+00:00","article_modified_time":"2026-04-08T12:58:29+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62635#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62635"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline","datePublished":"2026-04-08T12:58:27+00:00","dateModified":"2026-04-08T12:58:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62635"},"wordCount":721,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Gilead Sciences","NASDAQ: GILD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62635#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62635","url":"https:\/\/flcube.com\/?p=62635","name":"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-08T12:58:27+00:00","dateModified":"2026-04-08T12:58:29+00:00","description":"Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a German biotechnology company specializing in next-generation antibody-drug conjugates (ADCs), for $3.15 billion upfront plus up to $1.85 billion in contingent milestone payments. The acquisition significantly strengthens Gilead's oncology pipeline with two clinical-stage ADC assets targeting platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), and multiple solid tumor types.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62635#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62635"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62635#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62635"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62635\/revisions"}],"predecessor-version":[{"id":62636,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62635\/revisions\/62636"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}